Alkem Laboratories Limited
ALKEM.NS
₹5181.00
▼ 1.17%
Alkem Laboratories bucked the pharma sector's upbeat mood, slipping 1.17% to ₹5181 with no specific news behind the dip. The stock's recent performance has been underwhelming on a longer horizon too, down 2.85% over one year and a sharper 9.10% over two years, even though it has managed modest gains of 6.67% and 12.21% over five and ten years respectively. Twenty analysts cover the stock with an average target of ₹5948.55, well above current levels, though there's no clear consensus rating attached to that view.
CAGR Performance
| 1 Year | 2 Years | 5 Years | 10 Years |
|---|---|---|---|
| -3.62% | -9.90% | 6.20% | 12.24% |
Analyst Consensus
Average Target Price: ₹5948.55 (range ₹4590.00 - ₹6850.00) based on 20 analysts
Strong Buy: 6
Buy: 7
Hold: 4
Sell: 3
Strong Sell: 0
Related News
| Aug 14, 2026 | Alkem Laboratories Limited Share Price Falls 2.28% Today (Aug 14, 2026) |
| Aug 14, 2026 | Alkem Laboratories Q1 Consol Revenue From Operations 37.4 Billion Rupees |
No comments:
Post a Comment